Solid tumor therapy: Manipulation of the vasculature with TNF

Technology in Cancer Research and Treatment

Volumn 2, Issue 3, 2003, Pages 195-203

  Ten Hagen, Timo L M ^a   Eggermont, A M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Isolated perfusion; Solid tumor; Stealth liposomal doxorubicin; Tumor necrosis factor alpha; Tumor associated vasculature

Indexed keywords

BLEOMYCIN; CISPLATIN; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; LIPOSOME; MACROGOL; MELPHALAN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ANIMAL CELL; APOPTOSIS; CANCER INHIBITION; CANCER THERAPY; CELL NUCLEUS MEMBRANE; CLINICAL TRIAL; CYTOTOXICITY; DILUTION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDICATION; DRUG TARGETING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; EXTRAVASATION; HUMAN; HUMAN CELL; HYPOTENSION; INHIBITION KINETICS; LIMB PERFUSION; LIVER PERFUSION; MACROMOLECULE; MAXIMUM TOLERATED DOSE; NONHUMAN; REVIEW; SKIN TOXICITY; SOFT TISSUE SARCOMA; SOLID TUMOR; TARGET CELL; TUMOR VASCULARIZATION; VASOCONSTRICTION;

EID: 0141792648     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460300200303     Document Type: Review

References (97)

1. Folkman, J., Ingber, D. Inhibition of Angiogenesis. Semin Cancer Biol. 3, 89-96 (1992).
2. Jain, R. K. Delivery of Novel Therapeutic Agents in Tumors: Physiological Barriers and Strategies. J. Natl. Cancer Inst. 81, 570-576 (1989).
3. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., Folkman, J. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth. Cell. 88, 277-285 (1997).
4. Kerbel, R., Folkman, J. Clinical Translation of Angiogenesis Inhibitors. Nat. Rev. Cancer. 2, 727-739 2002.
5. Huang, X., Molema, G., King, S., Watkins, L., Edgington, T. S., Thorpe, P. E. Tumor Infarction in Mice by Antibody-directed Targeting of Tissue Factor to Tumor Vasculature. Science. 275, 547-550 (1997).
6. Ruegg, C., Yilmaz, A., Bieler, G., Bamat, J., Chaubert, P., and Lejeune, F. J. Evidence for the Involvement of Endothelial Cell Integrin alphaVbeta3 in the Disruption of the Tumor Vasculature Induced by TNF and IFN-gamma. Nat. Med. 4, 408-414 (1998).
7. Brooks, P. C., Silletti, S., von Schalscha, T. L., Friedlander, M., Cheresh, D. A. Disruption of Angiogenesis by PEX, A Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity. Cell. 92, 391-400 (1998).
8. Browder, T., Butterfield, C. E., Kraling, B. M., Shi, B., Marshall, B., O'Reilly, M. S., Folkman, J. Antiangiogenic Scheduling of Chemotherapy Improves Efficacy Against Experimental Drug-resistant Cancer. Cancer Res. 60, 1878-86 (2000).
9. ten Hagen, T. L. M., Eggermont, A. M. M., Lejeune F. J. TNF is Here to Stay - Revisited. Trends Immunol. 22, 127-129 (2001).
10. Jain, R. K. Delivery of Novel Therapeutic Agents in Tumors: Physiological Barriers and Strategies. J. Natl. Cancer Inst. 81, 570-576 (1989).
11. Yuan, F., Leunig, M., Huang, S. K., Berk, D. A., Papahadjopoulos, D., Jain, R. K. Microvascular Permeability and Interstitial Penetration of Sterically Stabilized (Stealth) Liposomes in a Human Tumor Xenograft. Cancer Res. 54, 3352-3356 (1994).
12. Dvorak, H. F., Nagy, J. A., Dvorak, J. T., and Dvorak, A. M. Identification and Characterization of the Blood Vessels of Solid Tumors that are Leaky to Circulating Macromolecules. Am. J. Pathol. 133, 95-109 (1988).
13. Kohn, S., Nagy, J. A., Dvorak, H. F., Dvorak, A. M. Pathways of Macromolecular Tracer Transport Across Venules and Small Veins. Structural Basis for the Hyperpermeability of Tumor Blood Vessels. Lab. Invest. 67, 596-607 (1992).
14. Creech, O., Krementz, E., Ryan, E., Winblad, J. Chemotherapy of Cancer: Regional Perfusion Utilising an Extracorporeal Circuit. Ann. Surg. 148, 616-632 (1958).
15. Benckhuijsen, C., Kroon, B. B., van Geel, A. N., et al. Regional Perfusion Treatment with Melphalan for Melanoma in a Limb: An Evaluation of Drug Kinetics. Eur. J. Surg. Oncol. 14, 157-163 (1988).
16. Thompson, J. F., Gianoutsos, M. P. Isolated Limb Perfusion for Melanoma - Effectiveness and Toxicity of Cisplatin Compared with that of Melphalan and Other Drugs. World J. Surg. 16, 227-233 (1992).
17. Klaase, J. M., Kroon, B. B. R., Van Geel, A. N., Eggermont, A. M. M., Franklin H. R. Systemic Leakage During Isolated Limb Perfusion for Melanoma. Br. J. Surg. 80, 1124-1126 (1993).
18. Wieberdink, K., Benckhuijsen, C., Braat, R. P., Van Slooten, E. A., Olthuis, G. A. A. Dosimetry in Isolation Perfusion of the Limbs by Assessment of Perfused Tissue Volume and Grading of Toxic Tissue Reactions. Eur. J. Cancer Clin. Oncol. 18, 905-910 (1982).
19. Eggermont, A. M. M. Treatment of Melanoma Intransit Metastases Confined to the Limb. Cancer Surveys 26, 335-349 (1996).
20. Omlor, G., Gross, G., Ecker, K. W., Burger, I., Feifel, G. Optimization of Isolated Hyperthermic Limb Perfusion. World J. Surg. 16, 1117-1119 (1993).
21. de Wilt, J. H. W., Manusama, E. R., van Tiel., S. T., Van IJken, M. G. A., ten Hagen, T. L. M., and Eggermont, A. M. M. Prerequisites for Effective Isolated Limb Perfusion Using Tumor Necrosis Alpha and Melphalan in Rats. Br. J. Cancer. 80, 161-166 (1999).
22. van IJken, M. G. A., van Etten, B., de Wilt, J. H. W., van Tiel, S. T., ten Hagen, T. L. M., Eggermont, A. M. M. Tumor Necrosis Factor-alpha Augments Tumor Effects in Isolated Hepatic Perfusion with Melphalan in a Rat Sarcoma Model. J. Immunother. 23, 449-455 (2000).
23. van IJken., M. G., de Bruijn., E. A., de Boeck., G., ten Hagen., T. L. M., van der Sijp., J. R. M., Eggermont., A. M. M. Isolated Hypoxic Hepatic Perfusion with Tumor Necrosis Factor-alpha, Melphalan and Mitomycin C Using Balloon Catheter Techniques: A Pharmacokinetic Study in Pigs. Ann. Surg. 228, 763-770 (1998).
24. Bangham., A. D., Standish., M. M., Watkins., J. C. Diffusion of Univalent Ions Across the Lamellae of Swollen Phospholipids. J Mol. Biol. 13, 238-252 (1965).
25. Allen., T. M. Long-circulating (Sterically Stabilized) Liposomes for Targeted Drug Delivery. Trends. Pharmacol. Sci. 15, 215-220 (1994).
26. Woodle, M. C., Newman, M. S., Working, P. K. Biological Properties of Sterically Stabilized Liposomes. In: Stealth Liposomes. (eds.) D. Lasic and F. Martin. pp. 103-117, Boca Raton: CRC Press. (1995).
27. Gabizon, A., Martin, F. Polyethylene Glycol-coated (pegylated) Liposomal Doxorubicin. Rationale for Use in Solid Tumours. Drugs 54, 15-21 (1997).
28. Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., Jain, R. K. Vascular Permeability in a Human Tumor Xenograft: Molecular Size Dependence and Cutoff Size. Cancer Res. 55, 3752-3756 (1995).
29. Wu, N. Z., Da, D., Rudoll, T. L., Needham, D., Whorton, A. R., Dewhirst, M. W. Increased Microvascular Permeability Contributes to Preferential Accumulation of Stealth Liposomes in Tumor Tissue. Cancer Res. 53, 3765-3770 (1993).
30. van der Veen, A. H., Eggermont, A. M. M., Seynhaeve, A. L. B., van Tiel, ten Hagen, T. L. M. Biodistribution and Tumor Localization of Stealth Liposomal Tumor Necrosis Factor-alpha in Soft Tissue Sarcoma Bearing Rats. Int. J. Cancer. 77, 901-906 (1998).
31. Gabizon, A. Tailoring Liposomes for Cancer Drug Delivery: From the Bench to the Clinic. Ann. Biol. Clin. 51, 811-813 (1993).
32. Coukell, A. J. Spencer, C. M. Polyethylene Glycol-liposomal Doxorubicin. A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in the Management of AIDS-related Kaposi's Sarcoma. Drugs. 53, 520-538 (1997).
33. Northfelt, D. W., Dezube, B. J., Thommes, J. A., Miller, B. J., Fischl, M. A. X., Friedman-Kien A, Kaplan, L. D., Du Mond, C., Mamelok, R. D., Henry, D. H. Pegylated-liposomal Doxorubicin Versus Doxorubicin, Bleomycin, and Vincristine in the Treatment of AIDS-related Kaposi's Sarcoma: Results of a Randomized Phase III Clinical Trial. J. Clin. Oncol. 16, 2445-2451 (1998).
34. Alberts, D. S., Garcia, D. J. Safety Aspects of Pegylated Liposomal Doxorubicin in Patients with Cancer. Drugs. 54, 30-35 (1997).
35. Muggia, F. M. Clinical Efficacy and Prospects for Use of Pegylated Liposomal Doxorubicin in the Treatment of Ovarian and Breast Cancers. Drugs. 54, 22-29 (1997).
36. Cay, O., Kruskal, J. B., Nasser, I., Thomas, P., Clouse, M. E. Liver Metastases from Colorectal Cancer: Drug Delivery with Liposome-encapsulated Doxorubicin. Radiology. 205, 95-101 (1997).
37. Debs, R. J., Duzgunes, N., Brunette, E. N., Fendly, B., Patton, J., Philip, R. Liposome-associated Tumor Necrosis Factor Retains Bioactivity in the Presence of Neutralizing Anti-tumor Necrosis Factor Antibodies. J. Immunol. 143, 1192-1197 (1989).
38. Nii, A., Fan, D., Fidler, I. J. Cytotoxic Potential of Liposomes Containing Tumor Necrosis Factor-alpha Against Sensitive and Resistant Target Cells. J. Immunother. 10, 13-19 (1991).
39. Utsumi, T., Hung, M. C., Klostergaard, J. Preparation and Characterization of Liposomal-lipophilic Tumor Necrosis Factor. Cancer Res. 51, 3362-3366 (1991).
40. Kedar, E., Palgi, O., Golod, G., Babai, I., Barenholz, Y. Delivery of Cytokines by Liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha Show Improved Pharmacokinetics and Biological Activity and Reduced Toxicity in Mice. J. Immunother. 20, 180-193 (1997).
41. Klostergaard, J., Utsumi, T, Macatee, S., Suen, T. C., Leroux, E., Levitan, A., Hung, M. C. Characterization and Modeling of Monocyte/ macrophage Presentation of Membrane TNF. In: Tumor Necrosis Factor: Structure-function Relationship and Clinical Application. (eds.) T. Osawa and B. Bonavida. pp. 101-110, Basel: Karger (1992).
42. Saito, M., Fan, D., Lachman, L. B. Antitumor Effects of Liposomal IL1 Alpha and TNF Alpha Against the Pulmonary Metastases of the B16F10 Murine Melanoma in Syngeneic Mice. Clin. Exp. Metastasis. 13, 249-259 (1995).
43. Kedar, E., Rutkowski, Y., Braun, E., Emanuel, N., Barenholz, Y. Delivery of Cytokines by Liposomes. I. Preparation and Characterization of Interleukin-2 Encapsulated in Long-circulating Sterically Stabilized Liposomes. J. Immunother. Emphasis. Tumor Immunol. 16, 47-59 (1994).
44. Coley, W. B. The Therapeutic Value of the Mixed Toxins of the Streptococcus of Erysipelas and Bacillus Prodigious in the Treatment of Inoperable Malignant Tumors. Am. J. Med. Sci. 112, 251-281 (1896).
45. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., Williamson, B. An Endotoxin-induced Serum Factor that Causes Necrosis of Tumors. Proc. Natl. Acad. Sci. USA. 72, 3666-3670 (1975).
46. Sidhu, R. S. Bollon, A. P. Tumor Necrosis Factor Activities and Cancer Therapy - A Perspective. Pharmacol. Ther. 57, 79-128 (1993).
47. Fajardo, L. F., Kwan, H. H., Kowalski, J., Prionas, S. D., Allison, A. C. Dual Role of Tumor Necrosis Factor-alpha in Angiogenesis. Am. J. Pathol. 140, 539-544 (1992).
48. Pennica, D., Nedwin, G. E., Hayflick, J. S., Seeburg, P. H., Derynck, R., Palladino, M. A, Kohr, W. J., Aggarwal, B. B., Goeddel, D. V. Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin. Nature. 312, 724-729 (1984).
49. Hieber, U. Heim, M. E. Tumor Necrosis Factor for the Treatment of Malignancies. Oncology. 51, 142-153 (1994).
50. Brouckaert, P. G., Leroux-Roels, G. G., Guisez, Y., Tavernier, J., Fiers, W. In vivo Anti-tumour Activity of Tecombinant Human and Murine TNF, Alone and in Combination with Murine IFN-gamma, on a Syngeneic Murine Melanoma. Int. J. Cancer. 38, 763-769 (1986).
51. Bartsch, H. H., Pfizenmaier, K., Schroeder, M., Nagel, G. A. Intralesional Application of Recombinant Human Tumor Necrosis Factor Alpha Induces Local Tumor Regression in Patients with Advanced Malignancies. Eur. J. Cancer Clin. Oncol. 25, 287-291 (1989).
52. Eggermont, A. M. M., Schraffordt Koops, H., Klausner, J. M., Lienard, D., Kroon, B. B. R., Schlag, P. M., Ben-Ari, G., Lejeune, F. J. Isolation Limb Perfusion with Tumor Necrosis Factor Alpha and Chemotherapy for Advanced Extremity Soft Tissue Sarcomas. Semin. Oncol. 24, 547-555 (1997).
53. Ruggiero, V., Latham, K., Baglioni, C. Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells. J. Immunol. 138, 2711-2717 (1987).
54. Watanabe, N., Niitsu, Y., Yamauchi, N., Ohtsuka, Y., Sone, H., Neda, H., Maeda, M, Urushizaki, I. Synergistic Cytotoxicity of Recombinant Human TNF and Various Anti-cancer Drugs. Immunopharmacol. Immunotoxicol. 10, 117-127 (1988).
55. van der Veen, A. H., ten Hagen, T. L. M., Seynhaeve, A. L. B., Eggermont, A. M. M. Lack of Cell-cycle Specific Effects of Tumor Necrosis Factor-alpha on Tumor Cells In Vitro: Implications for Combination Tumor Therapy with Doxorubicin. Cancer Invest. 20, 499-508 (2002).
56. Lienard, D., Ewalenko, P., Delmotte J. J, Renard N, Lejeune F. J. High-dose Recombinant Tumor Necrosis Factor Alpha in Combination with Interferon Gamma and Melphalan in Isolation Perfusion of the Limbs for Melanoma and Sarcoma. J. Clin. Oncol. 10, 50-62 (1992).
57. Lejeune, F. J., Lienard, D., Leyvraz, S., Mirimanoff, R. O. Regional Therapy of Melanoma. Eur J. Cancer 29A, 606-612 (1993).
58. Hill, S., Fawcett, W. J., Sheldon, J., Soni, N., Williams, T., Thomas, J. M. Low Dose Tumor Necrosis Factor-alpha and Melphalan in Hyperthermic Isolated Limb Perfusion. Br. J. Surg. 80, 995-997 (1993).
59. Vaglini, M., Belli, F., Ammatuna, M., Inglese, M., Manzi, R., Prada, A., Persiani, L., Santinami, M., Santoro, N., Cascinelli, N. Treatment of Primary or Relapsing Limb Cancer by Isolation Perfusion with High-dose TNF, Gamma-IFN and Melphalan. Cancer. 73, 483-492 (1994).
60. Eggermont, A. M. M., Liénard, D., Schraffordt Koops, H., Kroon, B. B. R., Rosenkaimer, F., Klaase, J. M., Schmitz, P. I. M., Lejeune, F. J. High Dose Tumor Necrosis Factor-alpha in Isolation Perfusion of the Limb: Highly Effective Treatment for Melanoma in Transit Metastases or Unresectable Sarcoma. Reg. Cancer Treat. 7, 32-36 (1995).
61. Fraker, D. L., Alexander, H. R., Andrich, M., Rosenberg, S. A. Treatment of Patients with Melanoma of the Extremity using Hyperthermic Isolated Limb Perfusion with Melphalan, Tumor Necrosis Factor, and Interferon Gamma: Results of a Tumor Necrosis Factor Dose-escalation Study. J. Clin. Oncol. 14, 479-489 (1996).
62. Lienard, D., Eggermont, A. M. M., Schraffordt Koops, H., Kroon, B. B. R., Towse, G., Hiemstra, S., Schmitz, P., Clarke, J., Steinmann, G., Rosenkaimer, F., Lejeune, F. J. Isolated Limb Perfusion with Tumour Necrosis Factor-alpha and Melphalan with or without Interferon-gamma for the Treatment of In-transit Melanoma Metastases: A Multicentre Randomized Phase II Study. Melanoma Res. 9, 491-502 (1999).
63. Stehlin, J. S., de Ipolyi, P. D., Giovanella, B. C., Gutierrez, A. E., Anderson, R. F. Soft Tissue Sarcomas of the Extremity: Multidisciplinary Therapy Employing Hyperthermic Perfusion. Am. J. Surg. 130, 643-646 (1975).
64. Krementz, E. T., Carter, R. D., Sutherland, C. M., Hutton, I. Chemotherapy of Sarcomas of the Limbs by Regional Perfusion. Ann. Surg. 185, 555-564 (1977).
65. Klaase, J. M., Kroon, B. B. R., Benckhuysen, C., van Geel, A. N., Albus-Lutter, Ch. E., Wieberdink, J. Results of Regional Isolation Perfusion with Cytostatics in Patients with Soft Tissue Tumors of the Extremities. Cancer 64, 616-621 (1989).
66. Rossi, C. R., Vecchiato, A., Foletto, M., et al. Phase II Study on Neoadjuvant Hyperthermic-antiblastic Perfusion with Doxorubicin in Patients with Intermediate of High Grade Limb Sarcomas. Cancer 73, 2140-2146 (1994).
67. Filippo, E D., Calabro. A. M., Cavallari, A., et al. The Role of Hyperthermic Perfusion as a First Step in the Treatment of Soft Tissue Sarcomas of the Extremities. World J. Surg. 12, 332-339 (1988).
68. Eggermont, A. M. M., Liénard, D., Schraffordt Koops, H., Rosenkaimer, F., Lejeune, F. J. Treatment of Irresectable Soft Tissue Sarcomas of the Limbs by Isolation Perfusion with High Dose TNF-α in Combination with Gamma-Interferon and Melphalan. In: Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance. (eds.) Fiers W. and Buurman W. A. pp 239-243 Basel, Karger Verlag, (1993).
69. Eggermont, A. M. M., Schraffordt Koops, H., Lienard, D., et al. Isolated Limb Perfusion with High-dose Tumor Necrosis Factor-alpha in Combination with Interferon-gamma and Melphalan for Nonresectable Extremity Soft Tissue Sarcomas: A Multicenter Trial. J. Clin. Oncol. 14, 2653-65 (1996).
70. Eggermont, A. M. M., Schraffordt Koops, H., Klausner, J. M., et al. Isolated Limb Perfusion with Tumor Necrosis Factor and Melphalan for Limb Salvage in 186 Patients with Locally Advanced Soft Tissue Extremity Sarcomas. The Cumulative Multicenter European Experience. Ann. Surg. 224, 756-64 (1996).
71. Eggermont, A. M. M., Schraffordt Koops, H., Klausner, J. M., Schlag, P. M., Kroon, B. B. R., Gustafson, P., Steinmann, G., Lejeune, F. J. Limb Salvage by Isolation Limb Perfusion with Tumor Necrosis Factor Alpha and Melphalan for Locally Advanced Extremity Soft Tissue Sarcomas: Results of 270 Perfusions in 246 Patients. Proceed. ASCO. 11, 497 (abstract) (1997).
72. Fraker, D. L., Alexander, H. R., Andrich, M., et al. Palliation of Regional Symptoms of Advanced Extremity Melanoma by Isolated Limb Perfusion with Melphalan and High-Dose Tumor Necrosis Factor. Cancer J. Sci. Am. 1, 122 (1995).
73. Manusama, E. R., de Wilt, J. H. W., ten Hagen, T. L. M., Marquet, R. L., Eggermont, A. M. M. Toxicity and Antitumor Activity of Interferon-gamma Alone and in Combinations with TNF and Melphalan in Isolated Limb Perfusion in the BN175 Sarcoma Tumor Model in Rats. Oncol. Rep. 6, 173-177 (1999).
74. Seynhaeve, A. L. B., de Wilt, J. H. W., van Tiel. S. T., Eggermont, A. M. M., ten Hagen, T. L. M. Isolated Limb Perfusion with Actinomycin D and TNF-alpha Results in Improved Tumour Response in Soft-tissue Sarcoma-bearing Rats but is Accompanied by Severe Local Toxicity. Br. J Cancer. 86, 1174-1179 (2002).
75. Olieman, A. F. T., van Ginkel, R. J., Hoekstra, H. J., Mooyaart, E. L., Molenaar, W. M., and Koops, H. S. Angiographic Response of Locally Advanced Soft-tissue Sarcoma Following Hyperthermic Isolated Limb Perfusion with Tumor Necrosis Factor. Annals of Surgical Oncology 4, 64-69, (1997).
76. Eggermont, A. M. M., Schraffordt Koops, H., Lienard, D., Lejeune, F. J., Oukerk, M. Angiographic Observations Before and After High Dose TNF Isolated Limb Perfusion in Patients with Extremity Soft Tissue Sarcomas. Eur. J. Surg. Oncol. 20, 323-324 (1994).
77. de Wilt, J. H. W., ten Hagen, T. L. M., de Boeck, G., van Tiel, S. T., de Bruijn, E. A., Eggermont, A. M. M. Tumour Necrosis Factor Alpha Increases Melphalan Concentration in Tumour Tissue After Isolated Limb Perfusion. Br. J. Cancer 82, 1000-1003 (2000).
78. van der Veen, A. H., de Wilt, J. H. W., Eggermont, A. M. M., van Tiel, S. T., ten Hagen. T. L. M. TNF-α Augments Intratumoural Concentration of Doxorubicin in TNF-α-based Isolated Limb Perfusion in Rat Sarcoma Models and Enhances Antitumour Effects. Br. J. Cancer. 82, 973-980, (2000).
79. Lans, T. E., ten Hagen, T. L. M., van Horssen, R., Wu, P. C., van Tiel, S. T., Libutti, S. K., Alexander, H. R., Eggermont, A. M. M. Improved Antitumor Response to Isolated Limb Perfusion with Tumor Necrosis Factor After Upregulation of Endothelial Monocyte-activating Polypeptide II in Soft Tissue Sarcoma. Ann. Surg. Oncol. 9, 812-819 (2002).
80. Alexander, H. R., Brown, C. K., Bartlett, D. L., Libutti, S. K., Figg, W. D., Raje, S., Turner, E. Augmented Capillary Leak During Isolated Hepatic Perfusion (IHP) Occurs via Tumor Necrosis Factor-independent Mechanisms. Clin. Cancer Res. 4, 2357-2362 (1998).
81. Alexander, H. R., Jr., Bartlett, D. L., Libutti, S. K., Fraker, D. L., and Moser, T., Rosenberg, S. A. Isolated Hepatic Perfusion with Tumor Necrosis Factor and Melphalan for Unresectable Cancers Confined to the Liver. J. Clin. Oncol. 16, 1479-1489 (1998).
82. Fraker, D. L., Alexander, H. R., Thom, A. K. Use of Tumor Necrosis Factor in Isolated Hepatic Perfusion. Circulatory Shock. 44, 45-50 (1994).
83. de Vries, M. R., Rinkes, I. H., van de Velde, C. J., Wiggers, T., Tollenaar, R. A. X., Kuppen, P. J., Vahrmeijer, A. L., Eggermont, A. M. M. Isolated Hepatic Perfusion with Tumor Necrosis Factor Alpha and Melphalan: Experimental Studies in Pigs and Phase I Data From Humans. Recent. Results. Cancer Res. 147, 107-119 (1998).
84. Lindner, P., Fjalling, M., Hafstrom, L., Kierulff-Nielsen, H., Mattsson, J., Schersten, T., Rizell, M., Naredi, P. Isolated Hepatic Perfusion with Extracorporeal Oxygenation using Hyperthermia, Tumour Necrosis Factor Alpha and Melphalan. Eur. J. Surg. Oncol. 25, 179-185 (1999).
85. Borel Rinkes, I. H., de Vries, M. R., Jonker, A. M., Swaak, T. J., Hack, C. E., Nooyen, P. T., Wiggers, T., and Eggermont, A. M. M. Isolated Hepatic Perfusion in the Pig with TNF-alpha with and without Melphalan. Br. J. Cancer 75, 1447-1453 (1997).
86. van IJken, M. G. A., de Bruijn, E. A., de Boeck, G., ten Hagen, T. L. M., van der Sijp, J. R. M., and Eggermont, A. M. M. Isolated Hypoxic Hepatic Perfusion with Tumor Necrosis Factor-alpha, Melphalan and Mitomycin C Using Balloon Catheter Techniques: A Pharmacokinetic Study in Pigs. Ann. Surg. 228, 763-770 (1998).
87. Borel Rinkes, I. H., de Vries, M. R., Jonker, A. M., Swaak, T. J., Hack, C. E., Nooyen, P. T. G. A., Wiggers, T., Eggermont, A. M. M. Isolated Hepatic Perfusion in the Pig with TNF-alpha with and without Melphalan. Br. J. Cancer 75, 1447-1453 (1997).
88. van IJken, M. G. A., van Etten, B., de Wilt, J. H. W., van Tiel, S. T., ten Hagen, T. L. M., Eggermont, A. M. M. Tumor Necrosis Factor-alpha Augments Tumor Effects in Isolated Hepatic Perfusion with Melphalan in a Rat Sarcoma Model. J. Immunother. 23, 449-455 (2000).
89. van Etten, B., de Vries, M. R., van IJken, M. G. A., Lans, T. E., Guetens, G., Ambagtsheer, G., van Tiel, S. T., de Boeck, G., de Bruijn, E. A., Eggermont, A. M. M., ten Hagen, T. L. M. Degree of Tumour Vascularity Correlates with Drug Accumulation and Tumour Response upon TNF-alpha-based Isolated Hepatic Perfusion. Br. J. Cancer. 88, 314-319 (2003).
90. ten Hagen, T. L. M., van der Veen, A. H., Nooijen, P. T. G. A., van Tiel, S. T., Seynhaeve, A. L. B., Eggermont, A. M. M. Low-dose Tumor Necrosis Factor-alpha Augments Antitumor Activity of Stealth Liposomal Doxorubicin (DOXIL) in Soft Tissue Sarcoma-bearing Rats. Int. J. Cancer. 87, 829-837 (2000).
91. Kim, D. W., Andres, M. L., Li, J., Kajioka, E. H., Miller, G. M., Seynhaeve, A. L. B., ten Hagen, T. L. M., Gridley, D. S. Liposome-encapsulated Tumor Necrosis Factor-alpha Enhances the Effects of Radiation Against Human Colon Tumor Xenografts. J. Interferon Cytokine Res. 21, 885-897 (2001).
92. Kim, D. W., Andres, M. L., Kajioka, E. H., Dutta-Roy, R., Miller, G. M., Seynhaeve, A. L. B., ten Hagen, T. L. M., Gridley, D. S. Modulation of Innate Immunological Factors by STEALTH Liposome-encapsulated Tumor Necrosis Factor-alpha in a Colon Tumor Xenograft Model. Anticancer Res. 22, 777-788 (2002).
93. Kim, D. W., Andres, M. L., Miller, G. M., Cao, J. D., Green, L. M., Seynhaeve, A. L. B., ten Hagen, T. L. M., Gridley, D. S. Immunohistological Analysis of Immune Cell Infiltration of a Human Colon Tumor Xenograft after Treatment with Stealth Liposome-encapsulated Tumor Necrosis Factor-alpha and Radiation. Int. J. Oncol. 21, 973-979 (2002).
94. Renard, N., Nooijen, P. T., Schalkwijk, L., De Waal, R. M., Eggermont, A. M., Lienard, D., Kroon, B. B., Lejeune, F. J., Ruiter, D. J. VWF Release and Platelet Aggregation in Human Melanoma after Perfusion with TNF Alpha. J. Pathol. 176, 279-287 (1995).
95. Nooijen, P. T. G. A., Eggermont, A. M. M., Schalkwijk, L., Henzen-Logmans, S., de Waal, R. M. W., Ruiter, D. J. Complete Response of Melanoma-in-transit Metastasis After Isolated Limb Perfusion with Tumor Necrosis Factor Alpha and Melphalan without Massive Tumor Necrosis: A Clinical and Histopathological Study of the Delayed-type Reaction Pattern. Cancer Res. 58, 4880-4887 (1998).
96. Kristensen, C. A., Nozue, M., Boucher, Y., Jain, R. K. Reduction of Interstitial Fluid Pressure after TNF-alpha Treatment of Three Human Melanoma Xenografts. Br. J. Cancer. 74, 533-536 (1996).
97. Suzuki, S., Ohta, S., Takashio, K., Nitanai, H., and Hashimoto, Y. Augmentation for Intratumoral Accumulation and Anti-tumor Activity of Liposome-encapsulated Adriamycin by Tumor Necrosis Factor-alpha in Mice. Int. J. Cancer. 46, 1095-1100 (1990).